Tessera
Folgen

Paolo Tarantino, MD

@ptarantinomd.bsky.social

Breast Medical Oncologist, Advanced Fellow Dana-Farber | Harvard | PhD Unimi. SoMe Editor ESMO Open. Interested in breast oncology, HER2, ADCs and good music.

21 Posts2207 Follower137 Folgt
OncoDaily@oncodaily.bsky.social · last yr.

Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center - Paolo Tarantino @ptarantinomd.bsky.social @stolaney1.bsky.social @dfcibreastonc.bsky.social oncodaily.com/blog/paolo-t... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Paolo Tarantino: Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center - OncoDaily

Paolo Tarantino: Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center / cancer, DFCI, OncoDaily, Oncology, Paolo Tarantino, Sara Tolaney

oncodaily.com

OncoDaily@oncodaily.bsky.social · last yr.

Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador @ptarantinomd.bsky.social @myesmo.bsky.social oncodaily.com/blog/paolo-t... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOBreast25 #ESMO

Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador - OncoDaily

Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador / Breast Cancer, cancer, ESMO, ESMO Ambassadors, ESMO Breast 25, OncoDaily, Oncology, Paolo

oncodaily.com

OncoDaily@oncodaily.bsky.social · last yr.

Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer @ptarantinomd.bsky.social oncodaily.com/blog/paolo-t... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADCs #BreastCancer

Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer - OncoDaily

Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer / Breast Cancer, cancer, Dana-Farber Cancer Institute, OncoDaily,

oncodaily.com

Paolo Tarantino, MD@ptarantinomd.bsky.social · last yr.

2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes. Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:

Bild
Julia Maués@itsnotpink.bsky.social · 2y ago

No standing ovations at #SABCS24, but maybe there should have been! 🎤 (Granted, I didn’t catch everything in the room.) For MBC, the #PATINA and #EMBER data bring meaningful progress for patients with ER+ & triple-positive breast cancer. Exciting strides being made.

Ilana Schlam@ilanaschlam.bsky.social · 2y ago

Wrapping up another fantastic #SABCS! Amazing, practice-changing data were presented. I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease! #SABCS24 @oncoalert.bsky.social

Paolo Tarantino, MD@ptarantinomd.bsky.social · 2y ago

Outstanding spotlight poster discussion by Thomas Grinda from Gustave Roussy. Promising results with the 1L combination of chemo, IO and VEGF blockade for mTNBC. Will the inclusion of IO in the combo change the story of VEGF, previously thought not to improve long-term outcomes for breast cancer?

Paolo Tarantino, MD@ptarantinomd.bsky.social · 2y ago

#SABCS24 day 1 kicks off with an interesting @FDAOncology special session on drug approval. First talk tackles the approval of adjuvant ribociclib per NATALEE. Two post-marketing commitments: to provide efficacy in a broader diverse population, and to provide updates on OS. #bcsm

Bild